ClinicalTrials.gg
CompletedNCT00394251Updated Nov 25, 2019Results posted

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

A Phase 2 interventional study of Adriamycin and Cytoxan (AC) and ABI-007 in Breast Cancer, sponsored by Celgene. Completed at 27 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
20th of 108
197 · median 60
Started
2006
with 8 others
Phase 2
67 of 108
9 open now
Registered
13th of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 20th largest by enrollment, is one of 9 that started in 2006, is one of 67 in phase 2, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Adjuvant therapy
  • Bevacizumab
  • Abraxane
  • Early stage breast cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient was eligible for inclusion in this study only if all of the following criteria were met:

  1. Female, age greater than or equal to 18 to less than or equal to 70 years old.
  2. Estrogen receptor (ER) and progesterone receptor (PR) status have been determined.
  3. Operable, confirmed adenocarcinoma of the breast
  4. Must have met 1 of the following criteria:

    • T1-3, N1-3, M0, regardless of ER or PR status.
    • T > 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.
    • T > 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative
    • T > 1 cm, N0, M0, ER or PR positive and grade 3
  5. Patients with one sentinel lymph node 0.2-2 mm in size were not required to undergo completion axillary dissection unless only 1 sentinel lymph node was examined. This completion axillary dissection was optional if 1 out of 2 or more sentinel lymph nodes was positive for a micrometastasis. Therefore if 1 of 1 sentinel lymph node was positive for micrometastasis(0.2-2 mm), then a completion axillary dissection was required.
  6. Patients with more than one sentinel node micrometastasis or 1 node with a micrometastasis > 2 mm and/or T3 disease must have undergone completion, standard axillary dissection. -Note: the following were not eligible-

    T1b,c,N0M0 and ER or PR positive and grade 1 or 2 Tx tumors (regardless of nodal status) T4 disease [i.e., patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes

    • Note: Sentinel lymph node micrometastasis \< 0.2 mm in considered N0 disease
  7. Negative surgical margins on lumpectomy or mastectomy specimen (no ink on invasive cancer and no ink on ductal carcinoma in situ [DCIS]).
  8. (ECOG) performance status 0-1
  9. Normal (ECG, as assessed by the investigator).
  10. No pre-existing peripheral neuropathy.
  11. It had not been longer than 84 days since the date of definitive surgery (eg, mastectomy or in the case of a breast-sparing procedure, axillary dissection).
  12. Laboratory values were to be as follows:

    • White blood cell count: > or equal to 3,000/mm\^3
    • :> or equal to 1,500/mm\^3
    • :> or equal to 100,000/mm\^3
    • : > or equal to 8g/dL
    • :\< or equal to the institution's
    • Creatinine: \< or equal to 1.7 mg/dL
    • (AST) and alanine aminotransferase (ALT) and alkaline phosphatase could be up to 2.5 times the institutional ULN.
  13. All staging studies including physical exam, chest x-ray, and bone scan had to show no evidence of metastatic disease, including suspicious lymphadenopathy or skin nodules on physical exam. A chest x-ray and bone scan were mandatory; however, all other staging studies were at the treating physician's discretion. Any other staging test (eg, Computed Tomography [CT] scans, magnetic resonance imaging [MRI] studies, ultrasound of abdomen, Positron Emission Tomography [PET] scans must have been negative for metastatic disease. An abdominal CT scan or PET scan was mandatory for patients with liver function tests elevated above the upper limit of normal (ULN) to rule out metastatic disease. If the patient had a staging PET scan then a bone scan was not necessary, but a chest x-ray was required.
  14. Patient had a negative serum pregnancy test \< or equal to 14 days of the first dose of study drug (patients of ).
  15. If fertile, patient had agreed to us an acceptable method of to avoid pregnancy [Note: oral contraceptives were not allowed] for the duration of chemotherapy and hormonal therapy and for 6 months thereafter.
  16. If obese, a patient must have been treated with doses calculated using his/her actual body surface area (BSA) (the physician must have been comfortable treating at the full BSA dose regardless of BSA).
  17. Patient had signed a Patient Form.

Exclusion criteria

Exclusion Criteria:

A patient was not eligible for inclusion in this study if any of the following criteria applied:

  1. Patients with positive breast cancer (IHC 3+ or FISH +) who were eligible for Herceptin therapy.
  2. Stage IV breast cancer (M1 disease on TNM staging system).
  3. Prior anthracycline, anthracenedione (mitoxantrone), or taxane therapy
  4. Neoadjuvant therapy for this breast cancer.
  5. Previous invasive cancers if treated \< 5 years prior to entering this study, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; the latter were not required to have occurred more than 5 years prior to study entry.
  6. Prior invasive breast cancer if diagnosed \< 5 years prior to entering study. Patients must have finished adjuvant hormonal therapy prior to registration. Patients with prior DCIS are eligible. Patients with DCIS who were treated with tamoxifen must have finished tamoxifen prior to registration.
  7. Serious medical illness, other than that treated by this study, which would limit survival to \< 4 years, or psychiatric condition that would prevent and compliance with study treatment.
  8. Uncontrolled or severe cardiovascular disease including recent (\< or equal to 12 months) myocardial infarction or unstable angina.
  9. Active uncontrolled bacterial, viral (including clinically defined Acquired Immune Deficiency Syndrome [AIDS]), or fungal infection.
  10. Patients with active or chronic hepatitis with abnormal liver function tests (LFTs) or patients who were known to be positive.
  11. Uncontrolled disease such as uncontrolled diabetes.
  12. Any prior history of hypertensive crisis or hypertensive encephalopathy.
  13. Any known central nervous system (CNS) disease.
  14. Known to any component of bevacizumab.
  15. No history of cerebrovascular accident or at any time.
  16. Active symptomatic vascular disease, e.g., aortic aneurysm or aortic dissection, and no peripheral vascular disease, e.g., claudication, within six months of study entry.
  17. No major surgical procedure, open , or significant traumatic injury within 28 days and no core biopsy or minor surgical procedure (excluding placement of a vascular access device) within seven days of study entry. No anticipated need for major surgical procedure during the course of study.
  18. No history of abdominal fistula, gastrointestinal perforation, or intra- abdominal process within six months of study entry.
  19. No serious non-healing wound, ulcer, or bone fracture.
  20. No proteinuria at screening as demonstrated by urine protein: urine creatinine (UPC) ratio of > or equal to 1.0 or urine dipstick for proteinuria > or equal to 2+ (patients discovered to have > or equal to 2+ proteinuria on dipstick urinalysis at baseline should have undergone a 24 hour urine collection and must have demonstrated \< or equal to 1g of protein in 24 hours to be eligible).
  21. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and /or diastolic blood pressure> 100 mmHg on antihypertensive medications) or (NYHA) Grade 2 or greater congestive heart failure.
  22. History or coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic acetyl salicylic acid (ASA)> or equal to 325 mg. per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH) for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.
  23. (LVEF) on cardiac echocardiography (ECHO) \< 50% (or institutional lower limit of normal [LLN]) and > or equal to 74%. LVEF of greater than 75% at baseline should have been re- reviewed and/or the test repeated as it could be falsely elevated.
  24. Patients who were receiving concurrent immunotherapy.
  25. A history of other within the last 5 years, which could affect the diagnosis or assessment of breast cancer recurrence or which could shorten a patient's survival.
  26. Patient had had an organ allograft.
  27. Patient was pregnant or breastfeeding.
  28. Patient was unable to comply with requirements of study.
  29. Patient was receiving any other drugs.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    AC --> ABI-007

    Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m\^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).

    Drug: Adriamycin and Cytoxan (AC) · Drug: ABI-007 · Drug: Bevacizumab · Drug: pegfilgrastim

  • Experimental
    AC --> Taxol

    Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m\^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).

    Drug: Adriamycin and Cytoxan (AC) · Drug: Taxol · Drug: Bevacizumab · Drug: pegfilgrastim

Interventions

  • DrugAdriamycin and Cytoxan (AC)

    Drug pages: Doxorubicin · Cyclophosphamide

    Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).

    Also known as: doxorubicin, cyclophosphamide

  • 260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)

    Also known as: Abraxane

  • DrugTaxol

    175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)

    Also known as: paclitaxel

  • 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).

    Also known as: Avastin®

  • 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.

    Also known as: Neulasta

06

What researchers measure

Primary outcomes

  1. Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy

    Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).

    Time frame: Month 7

  2. Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy

    Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 6 months after chemotherapy (month 10). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 6 months after chemotherapy (month 10).

    Time frame: Month 10

Secondary outcomes

  1. The Cumulative Dose of Taxane Delivered During Study

    The cumulative dose of taxane (Taxol or ABI-007) taken during the study (cycles 4-8 which is approximately weeks 9-16).

    Time frame: approximately week 9-16

  2. Mean Taxane Dose Intensity Per Week

    Cumulative taxane (ABI-007 or Taxol) dose divided by the number of weeks on taxane treatment.

    Time frame: approximately week 9-16

  3. Percent of Protocol Taxane Dose

    Percent of the protocol-defined taxane (ABI-007 or Taxol) dose that was actually taken by study participants.

    Time frame: approximately week 9-16

  4. Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays

    Counts of participants who * completed the protocol-defined treatment cycles, * had a dose interruption * had a dose reduction * had a dose delay. A dose delay refers to the delay of all interventions in the cycle. Dose modifications are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Use of pegfilgrastim is included in the summary.

    Time frame: up to Week 46

  5. Myelosuppression During Taxane Dosing Cycles

    Myelosuppression represented by neutropenia (low absolute neutrophil counts (ANC)) with severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). * Grade 1 = \<lower limit of normal (LLN)-1.5\*10\^9/L * Grade 2 = \<1.5 - 1.0\*10\^9/L * Grade 3 = \<1.0 - 0.5\*10\^9/L * Grade 4 = \<0.5\*10\^9/L Values are reported across all severity grades without assessment of relationship to taxane treatment, and also by relation to taxane treatment as reported by investigators.

    Time frame: Weeks 9-16

  6. Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation

    Decreased left ventricular ejection fraction (LVEF) is an indication of cardiotoxicity. Change from baseline measurements to the final evaluation are summarized.

    Time frame: up to week 46

  7. Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)

    Summary of the most severe grades using the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for the following liver and renal function tests. Grade 0 = within normal range for all measurements. Alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST): * Grade 1 = \> upper limit of normal (ULN) - 2.5\*ULN * Grade 2= \>2.5-5.0\*ULN * Grade 3= \>5.0-20.0\*ULN * Grade 4= \>20.0\*ULN Bilirubin: * Grade 1= \>ULN - 1.5\*ULN * Grade 3= \>3.0 - 10.0\*ULN Creatinine: - Grade 1= \>ULN - 1.5\*ULN

    Time frame: Week 1 up to week 50

07

Results

Posted Jul 18, 2013

Participant flow

Multicenter study

Participant flow — Overall Study
MilestoneAC --> ABI-007AC --> Taxol
Started9899
At least one dose of taxane9393
Completed6161
Not completed3738
Withdrew: Adverse event75
Withdrew: Unacceptable toxicity2018
Withdrew: Physician decision11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject711
Withdrew: Non-compliance, pt moved, pt/inv agree22

Outcome measures

SecondaryThe Cumulative Dose of Taxane Delivered During Study

The cumulative dose of taxane (Taxol or ABI-007) taken during the study (cycles 4-8 which is approximately weeks 9-16).

Time frame:
approximately week 9-16
Reported as:
Mean · mg/m^2
The Cumulative Dose of Taxane Delivered During Study
mg/m^2AC --> ABI-007AC --> Taxol
The Cumulative Dose of Taxane Delivered During Study950.5 ± 199.86660.8 ± 99.52
SecondaryMean Taxane Dose Intensity Per Week

Cumulative taxane (ABI-007 or Taxol) dose divided by the number of weeks on taxane treatment.

Time frame:
approximately week 9-16
Reported as:
Mean · mg/m^2/week
Mean Taxane Dose Intensity Per Week
mg/m^2/weekAC --> ABI-007AC --> Taxol
Mean Taxane Dose Intensity Per Week118.82 ± 24.98382.60 ± 12.440
PrimaryParticipants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy

Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).

Time frame:
Month 7
Reported as:
Number · participants
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy
participantsABI-007 SubsetAC --> ABI-007Taxol SubsetAC --> Taxol
At least 1 AE at 3 Months65746577
Neurology: Neuropathy: Sensory36502835
Constitutional Symptoms: Fatigue16461032
Dermatology/Skin: Hair Loss/Alopecia (Scalp+Body)233117
Endocrine: Hot Flashes/Flushes1228522
Cardiac General: Hypertension418725
Pain: Arthralgia722819
Hemorrhage/Bleeding: Nasal11191018
Pain: Other - Extremity415722
Pain: Myalgia1020916
Dermatology/Skin: Nail Changes1422510
Constitutional Symptoms: Insomnia316511
Statistical analysis
  • ABI-007 Subset vs Taxol Subset · Fisher Exact · p = 0.641
SecondaryPercent of Protocol Taxane Dose

Percent of the protocol-defined taxane (ABI-007 or Taxol) dose that was actually taken by study participants.

Time frame:
approximately week 9-16
Reported as:
Mean · percentage of protocol-defined taxane
Percent of Protocol Taxane Dose
percentage of protocol-defined taxaneAC --> ABI-007AC --> Taxol
Percent of Protocol Taxane Dose91.40 ± 19.21894.40 ± 14.217
SecondarySummary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays

Counts of participants who * completed the protocol-defined treatment cycles, * had a dose interruption * had a dose reduction * had a dose delay. A dose delay refers to the delay of all interventions in the cycle. Dose modifications are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Use of pegfilgrastim is included in the summary.

Time frame:
up to Week 46
Reported as:
Number · participants
Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays
participantsAC --> ABI-007AC --> Taxol
Completed 4 cycles of Adriamycin/Cytoxan (AC)9595
Received pegfilgrastim for 4 cycles during AC9594
Completed 4 cycles of taxane8284
Completed 18 cycles of bevacizumab6161
One or more dose reduction: Adriamycin106
One or more dose reduction: Cytoxan95
One or more dose reduction: Taxane1216
One or more dose interruption: Adriamycin10
One or more dose interruption: Cytoxan31
One or more dose interruption: Taxane03
One or more dose interruption: Bevacizumab02
One or more delay in study regimen5048
Discontinued pegfilgrastim during AC cycles00
Administered pegfilgrastim during taxane cycles2313
SecondaryMyelosuppression During Taxane Dosing Cycles

Myelosuppression represented by neutropenia (low absolute neutrophil counts (ANC)) with severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). * Grade 1 = \<lower limit of normal (LLN)-1.5\*10\^9/L * Grade 2 = \<1.5 - 1.0\*10\^9/L * Grade 3 = \<1.0 - 0.5\*10\^9/L * Grade 4 = \<0.5\*10\^9/L Values are reported across all severity grades without assessment of relationship to taxane treatment, and also by relation to taxane treatment as reported by investigators.

Time frame:
Weeks 9-16
Reported as:
Number · participants
Myelosuppression During Taxane Dosing Cycles
participantsAC --> ABI-007AC --> Taxol
ANC (grades 1-4)5843
Taxane-related, grades 1-4118
Taxane-related, grades 3-465
SecondaryChange From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation

Decreased left ventricular ejection fraction (LVEF) is an indication of cardiotoxicity. Change from baseline measurements to the final evaluation are summarized.

Time frame:
up to week 46
Reported as:
Median · percentage of healthy LVEF
Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation
percentage of healthy LVEFAC --> ABI-007AC --> Taxol
Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation-1.0 ± 7.40-1.0 ± 93.40
SecondarySummary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)

Summary of the most severe grades using the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE) for the following liver and renal function tests. Grade 0 = within normal range for all measurements. Alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST): * Grade 1 = \> upper limit of normal (ULN) - 2.5\*ULN * Grade 2= \>2.5-5.0\*ULN * Grade 3= \>5.0-20.0\*ULN * Grade 4= \>20.0\*ULN Bilirubin: * Grade 1= \>ULN - 1.5\*ULN * Grade 3= \>3.0 - 10.0\*ULN Creatinine: - Grade 1= \>ULN - 1.5\*ULN

Time frame:
Week 1 up to week 50
Reported as:
Number · participants
Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)
participantsAC --> ABI-007AC --> Taxol
Alkaline phosphatase, Grade 06970
Alkaline phosphatase, Grade 12629
Alkaline phosphatase, Grade 210
ALT, Grade 06675
ALT, Grade 12423
ALT, Grade 251
ALT, Grade 410
AST, grade 07481
AST, grade 12017
AST, grade 211
AST, grade 310
Bilirubin, grade 09598
Bilirubin, grade 101
Bilirubin, grade 310
Creatinine, grade 09497
Creatinine, grade 122
PrimaryParticipants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy

Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 6 months after chemotherapy (month 10). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 6 months after chemotherapy (month 10).

Time frame:
Month 10
Reported as:
Number · participants
Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy
participantsABI-007 SubsetAC --> ABI-007Taxol SubsetAC --> Taxol
At least 1 AE at 6 Months49624665
Neurology: Neuropathy: Sensory25421519
Constitutional Symptoms: Fatigue1132418
Endocrine: Hot Flashes/Flushes723317
Cardiac General: Hypertension412718
Pain: Arthralgia417313
Pain: Myalgia81748
Pain: Other - Extremity16514
Dermatology/Skin: Nail Changes81336
Statistical analysis
  • ABI-007 Subset vs Taxol Subset · Fisher Exact · p = 0.323

Adverse events

Collected over Day 1 - up to week 50 (weeks 1-46 treatment, plus 30 days after last study dose). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC --> ABI-007—30/98 (30.6%)97/98 (99%)
AC --> Taxol—21/99 (21.2%)99/99 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventAC --> ABI-007AC --> Taxol
Febrile neutropeniaBlood and lymphatic system disorders7/985/99
Cardiac failure congestiveCardiac disorders0/984/99
PyrexiaGeneral disorders2/980/99
SepsisInfections and infestations2/980/99
PancytopeniaBlood and lymphatic system disorders2/980/99
Deep vein thrombosisVascular disorders2/980/99
Chest painGeneral disorders1/982/99
SyncopeNervous system disorders1/982/99
Appendicitis perforatedGastrointestinal disorders1/980/99
ArthralgiaMusculoskeletal and connective tissue disorders1/981/99
Most frequent other events
Showing 10 of 105
Most frequent other events
EventAC --> ABI-007AC --> Taxol
FatigueGeneral disorders81/9877/99
NauseaGastrointestinal disorders77/9879/99
AlopeciaSkin and subcutaneous tissue disorders61/9866/99
ArthralgiaMusculoskeletal and connective tissue disorders54/9848/99
AnaemiaBlood and lymphatic system disorders50/9844/99
ConstipationGastrointestinal disorders47/9840/99
MyalgiaMusculoskeletal and connective tissue disorders45/9841/99
EpistaxisRespiratory, thoracic and mediastinal disorders45/9838/99
HeadacheNervous system disorders42/9841/99
NeuropathyNervous system disorders39/9838/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)AC --> ABI-007AC --> TaxolTotal
Mean51.2 ± 9.2151.2 ± 9.2951.2 ± 9.23
Age, Customized
Age, Customized(participants)AC --> ABI-007AC --> TaxolTotal
>=65 years91120
< 65 years8988177
Sex: Female, Male
Sex: Female, Male(Participants)AC --> ABI-007AC --> TaxolTotal
Female9899197
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AC --> ABI-007AC --> TaxolTotal
Asian325
White, non-Hispanic, non-Latino7672148
White, Hispanic or Latino81725
Black, of African heritage10717
Other112
Region of Enrollment
Region of Enrollment(participants)AC --> ABI-007AC --> TaxolTotal
United States9899197
Weight
Weight(kg)AC --> ABI-007AC --> TaxolTotal
Mean78.63 ± 19.56178.78 ± 19.59578.71 ± 19.528
Menopausal Status
Menopausal Status(participants)AC --> ABI-007AC --> TaxolTotal
premenopausal504494
postmenopausal4855103
Stage at Primary Diagnosis
Stage at Primary Diagnosis(participants)AC --> ABI-007AC --> TaxolTotal
I: tumor <=2.0, lymph nodes clear, no metastasis10717
IIa: tumor <=2.0 cm, regional lymph node283563
IIb: tumor >2.0<5.0cm, regional lymph nodes322456
IIIa: tumor may be >5.0 cm, regional lymph nodes222345
IIIb: tumor extending to chest wall or skin000
IIIc: tumor with extensive lymph node involvement6915
IV: distant metastasis000
unknown011

4 further baseline measures are reported on the registry.

08

Study locations

27 sites
  • Birmingham, Alabama 35205, United States
  • Sedona, Arizona 86336, United States
  • Denver, Colorado 80220, United States
  • Torrington, Connecticut 06790, United States
  • Indianapolis, Indiana 46227, United States
  • Minneapolis, Minnesota 55404, United States
  • Columbia, Missouri 65201, United States
  • Saint Louis, Missouri 63136, United States
  • Henderson, Nevada 89052, United States
  • Raleigh, North Carolina 27607, United States
  • Eugene, Oregon 97401, United States
  • Greenville, South Carolina 29615, United States
  • Austin, Texas 78731, United States
  • Bedford, Texas 76022, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75246, United States
  • El Paso, Texas 79915, United States
  • Fort Worth, Texas 76104, United States
  • Fredericksburg, Texas 78624, United States
  • Houston, Texas 77024, United States
  • Longview, Texas 75601, United States
  • McAllen, Texas 78503, United States
  • Tyler, Texas 75702, United States
  • Waco, Texas 76712, United States
  • Fairfax, Virginia 22031, United States
  • Norfolk, Virginia 23502, United States
  • Vancouver, Washington 98684, United States
09

References and documents

Publications

  • Pippen J, Paul D, Vukelja S, Clawson A, Iglesias J. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Res Treat. 2011 Dec;130(3):825-31. doi: 10.1007/s10549-011-1678-9. Epub 2011 Oct 6. PubMed 21976055 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2006 to primary completion in Mar 2007, 7 months.

Results were first posted in Jul 2013, 6 years 4 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 7 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2006
First posted
Oct 31, 2006
StartActual
Aug 1, 2006
Primary completionActual
Mar 1, 2007
CompletionActual
Feb 1, 2008
Results first posted
Jul 18, 2013
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00394251
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 31, 2006
Start date
Aug 1, 2006
Primary completion
Mar 1, 2007
Completion
Feb 1, 2008
Results posted
Jul 18, 2013
Last update
Nov 25, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Paclitaxel

Start the discussion